Cutaneous Lymphomas -Part II: Other Cutaneous Lymphomas

Area of Science:

• Dermatology
• Hematology
• Oncology

Background:

• Primary cutaneous lymphomas (PCLs) are rare, comprising T-cell and B-cell types.
• T-cell lymphomas, excluding mycosis fungoides and Sézary syndrome, are uncommon (<5% of PCLs), typically aggressive, and cytotoxic.
• Cutaneous B-cell lymphomas (CBCLs) represent about 30% of PCLs and exhibit significant heterogeneity.

Purpose of the Study:

• To delineate the characteristics and clinical behavior of rare primary cutaneous T-cell lymphomas (CTCLs) and cutaneous B-cell lymphomas (CBCLs).
• To highlight the aggressive nature and management considerations for specific CTCL subtypes.
• To describe the varied presentations and prognoses of different CBCL subtypes.

Main Methods:

• Review of clinical and pathological features of primary cutaneous lymphomas.
• Classification of CTCLs and CBCLs based on established criteria.
• Analysis of clinical presentation, disease course, and treatment modalities.

Main Results:

• Rare CTCLs, distinct from mycosis fungoides and Sézary syndrome, are cytotoxic, aggressive, and often involve extracutaneous sites.
• CBCLs present as papules, nodules, or tumors, with variable morphology and distribution.
• Three main CBCL groups identified: follicle center lymphoma, indolent marginal zone lymphoma, and aggressive diffuse large B-cell lymphoma, leg type.

Conclusions:

• Management of aggressive CTCLs requires a multidisciplinary approach, potentially including intensive systemic therapy and bone marrow transplantation.
• CBCLs encompass a spectrum of diseases with distinct clinical behaviors, ranging from indolent to aggressive.
• Accurate classification of PCL subtypes is crucial for determining prognosis and guiding therapeutic strategies.